Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
2021 · European Urology Open Science · 14 citations
https://doi.org/10.1016/j.euros.2021.11.011
R
Ronald Kool
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
49
Papers
368
Citations
8
h-index
7
i10-index
Ronald Kool is an academic researcher from Gaertner (United States). The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Urinary and Genital Oncology Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 8, co-authored 42 publications.
ORCID: 0000-0001-7471-6456Papers by this author
worksEffect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer
2024 · International Journal of Radiation Oncology*Biology*Physics · 6 citations
https://doi.org/10.1016/j.ijrobp.2024.08.036
Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy
2022 · European Urology Open Science · 4 citations
https://doi.org/10.1016/j.euros.2022.06.009
Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
2023 · European Urology Open Science · 4 citations
https://doi.org/10.1016/j.euros.2023.09.003
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat